Muslih ÜRÜN, Yasin SEZGİN, Yonca YILMAZ ÜRÜN, Anıl UÇAN, Sinem GÜRCÜ, Fuzuli TUĞRUL

KANSER HASTALARININ İLAÇLA TEDAVİSİNDE FAZLA KİLONUN EK MALİYETİ

Giriş: Fazla kilo, normal aralığın üzerindeki bir ağırlığı ifade eder. Vücut kitle indeksi (VKİ), kilogram cinsinden ağırlığın metre cinsinden boyun karesine bölünmesiyle tanımlanır. Zayıf, normal kilolu, fazla kilolu ve obezitenin belirlenmesinde yaygın olarak kabul görmektedir. Kanser, dünyada kardiyovasküler hastalıklardan sonra en yaygın ölüm nedenidir ve kanser tedavisinde ilaç maliyetleri gelişmiş ülkelerde bile önemli bir ekonomik yük getirmektedir. Çalışmamızda 2021 yılında sadece Eskişehir Şehir Hastanesi'nde kiloya göre dozlanan ve intravenöz olarak hedefe yönelik tedavi ajanları alan hastaların yıllık ek maliyetini hesapladık. Materyal Yöntem: 2021 takvim yılı içinde tedavi gören, ilaç dozu vücut ağırlığına göre hesaplanan, intravenöz kullanılan hedefe yönelik ilaçlar çalışmamıza dahil edildi. Çalışmada vücut kitle indeksi (VKİ) (boyun kilogram/metre cinsinden karesi) hesaplandı. Fazla kilolar kilo olarak kaydedildi, VKİ 25 ve üzeri, üst sınır 25 olarak kaydedildi. Hastaların 129'u (%69,7) kadın, 56'sı (%30,3) erkek olmak üzere toplam 185 hasta vardı. Tartışma: 2021 yılında hastanemiz çalışmamızda kullandığımız altı ilaç için toplam 4.450.673 TL ödemiş olup, fazla kilolu olduğumuz için toplam 598.714 TL ödeme yapılmıştır. Ülkemizde 2021 yılında net asgari ücret 2850 TL oldu. 6 ilaca ödenen toplam ücret 1561 asgari ücrete, fazla kilo için ödenen ücret ise 210 asgari ücrete tekabül etti. Sonuç olarak, bu hasta grubunda tek bir medikal onkoloğun bulunduğu bir hastanenin ek maliyeti bile bize obezitenin tahmin edilenden daha önemli bir halk sağlığı gerçekliğini bir kez daha hatırlatmaktadır. Obezitenin önlenmesi ve tedavisi için daha fazla çabaya ihtiyaç olduğu açıktır.

Anahtar Kelimeler:

kanser, obezite, hedefe yönelik tedavi, maliyet

ADDITIONAL COST OF OVERWEIGHT IN MEDICATION OF CANCER PATIENTS

Introduction: Overweight refers to a weight above the normal range. Body mass index (BMI) is defined as weight in kilograms divided by the square of height in meters. It is widely accepted in the determination of underweight, normal weight, overweight, and obesity. Cancer is the most common cause of death in the world after cardiovascular diseases, and drug costs in cancer treatment bring a significant economic burden even in developed countries. In our study, we calculated the annual additional cost of patients who were dosed according to kilograms and received intravenous targeted therapy agents only in Eskişehir City Hospital in 2021. Material Method: Targeted drugs that received treatment within the 2021 calendar year, whose drug dose was calculated according to body weight, and which were used intravenously, were included in our study. Body mass index (BMI) (height squared in kilograms/meter) was calculated in the study. Excess weight was recorded in kilograms, with a BMI of 25 and above, with an upper limit of 25. There were 185 patients in total, 129 of them were female (69.7%) and 56 (30.3%) were male. Discussion: In 2021, our hospital paid a total of 4,450,673 Turkish liras for the six drugs we took in our study, and a total of 598,714 Turkish liras were paid due to being overweight. In our country, the net minimum wage in 2021 was 2850 Turkish lira. The total price paid for 6 drugs corresponded to the minimum wage of 1561, and the wage paid for overweight was equal to 210 minimum wage. As a result, even the additional cost of a hospital with a single medical oncologist in this patient group reminds us again of a more important public health reality of obesity than anticipated. It is obvious that more efforts are needed for the prevention and treatment of obesity.

Keywords:

cancer, obesity, targeted therapy, cost,

PDF

___

Bray GA. The Battle of the Bulge: A History of Obesity Research. Dorrance; 2007.
World Health Organisation. Obesity: preventing and managing the global epidemic: report of a WHO consultation. World Health Organ Tech Rep Ser 2000;8 94:1–253.
Grover SA, Kaouache M, Rempel P, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modeling study. Lancet Diabetes Endocrinol 2015; 3:114.
Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352:1138.
Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016; 388:776.
GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 2017; 377:13.
Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ 2016; 353:i2156.
Mather M, Scommegna P. Up to half of US premature deaths are preventable; behavioral factors key. Population Reference Bureau 2015. Available at: https://www.prb.org/resources/up-to-half-of-u-s-premature-deaths-are-preventable-behavioral-factors-key/ Accessed May 16, 2022.
Rueda-Clausen CF, Ogunleye AA, Sharma AM. Health Benefits of Long-Term Weight-Loss Maintenance. Annu Rev Nutr 2015; 35:475.
Lauby-Secretan B, Scoccianti C, Loomis D, et al. International Agency for Research on Cancer Handbook Working Group. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med 2016;375:794-8.
Steele CB, Thomas CC, Henley SJ, et al. Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity - United States, 2005-2014. MMWR Morb Mortal Wkly Rep 2017; 66:1052.
Weihrauch-Blüher S, Schwarz P, Klusmann JH. Childhood obesity: increased risk for cardiometabolic disease and cancer in adulthood. Metabolism 2019; 92:147.
Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev 2015; 95:727.
Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2007. Available at: http://seer.cancer.gov/csr/1975_2005 Accessed July 18, 2008
Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008;100:888–97.
US Department of Agriculture Economic Research Service. Food Safety Glossary. Available at: https://www.ers.usda.gov/topics/food-safety/ Accessed January 25, 2012.
Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ 2012; 31:219-30.
Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity:payer- and service-specific estimates. Health Aff (Millwood) 2009; 28:822-31.
Thompson D, Edelsberg J, Colditz GA, et al. Lifetime health and economic consequences of obesity. Arch Intern Med 1999; 159:2177-83.
Nelson R. Annual Cost of Cancer Care Reached $156 Billion. Available at: https://www.medscape.com/viewarticle/960516 Accessed Oct 08, 2021.